Académique Documents
Professionnel Documents
Culture Documents
Fariha Saleem
clonal stem cell diseases characterized by cytopenia(s),dysplasia in one or more of the major myeloid cell lines, ineffective haematopoiesis, and increased risk of development of acute myeloid leukaemia(AML).
exclusionary for a diagnosis of MDS if definitive morphologic and/or cytogenetic findings are present.
The dysplasia may be accompanied by an increase in
myeloblasts in the PB and BM but the no is < 20% , which is the requisite threshold recommended for the diagnosis of AML.
EPIDEMIOLOGY:
Affects older adults, with a median age of 70 years.
Annual incidence of MDS is : 3-5/100,000 persons. male predominance with a male to female ratio of 1.4:1
AETIOLOGY:
Primary or de novo MDS :
Possible etiologies for primary MDS include:
Benzene exposure
exposure to agricultural chemicals or solvents smoking
beyond.
therapy -related MDS are associated with a higher incidence of trilineage dysplasia, genetic abnormalities, evolution to AML and poor response to treatment.
FAB CLASSIFICATION:
SUBTYPE Refractory anaemia (RA) Refractory anaemia with ringed sideroblasts (RARS) Refractory anaemia with excess blasts (RAEB) Refractory anaemia with excess blasts in transformation (RAEBt) Chronic myelomonocytic leukaemia (CMML) BLOOD < 1% blasts < 1% blasts BONE MARROW Dysplasia < 5% blasts As for RA and > 15% ringed sideroblasts
< 5% blasts
Dysplasia 5 19% blasts Dysplasia 20 29% blasts or Auer rods Dysplasia < 30% blasts
< 5% blasts
> 1 10 9 /L monocytes
WHO CLASSIFICATION:
SUBTYPE Refractory cytopenias with unilineage dysplasia (RCUD) Refractory anaemia (RA) Refractory neutropenia (RN) Refractory thrombocytopenia (RT) Refractory anaemia with ring sideroblasts (RARS) Refractory cytopenia with multilineage dysplasia (RCMD) BLOOD Unicytopenia or bicytopenia BONE MARROW Dysplasia in > 10% of cells of one myeloid lineage only < 5% blasts < 15% ring sideroblasts
Anaemia
Erythroid dysplasia only > 15% ring sideroblasts Dysplasia in > 10% of cells in two or more myeloid lineages < 5% blasts < 15% ring sideroblasts
Cytopenia(s)
SUBTYPE
BLOOD
BONE MARROW
Refractory cytopenia with multilineage dysplasia and ring sideroblasts (RCMD- RS)
Cytopenia(s)
Dysplasia in > 10% of cells in two or more myeloid lineages < 5% blasts > 15% ring sideroblasts
BONE MARROW Dysplasia in < 10% of cells in one or more myeloid lineage Cytogenetic abnormality supportive of diagnosis < 5% blasts
Prominent megakaryocytes with hypolobated nuclei Isolated del(5q) cytogenetic abnormality < 5% blasts
Cytogenetic abnormalities
25 < 10 50 50 30 40 40 50 100
PATHOGENESIS:
The cardinal features of MDS are : Increased marrow proliferation Failure of stem cells to differentiate Increased marrow apoptosis.
The disease is of clonal origin
Chromosomal abnormalities are detectable in 30-
70% of patients.
three myeloid lineages (i.e. megakaryocytic, erythroid and granulocytic/monocytic). the presence of trilineage dysplasia and cytogenetic abnormalities provides irrefutable evidence for a multipotent stem/progenitor cell origin. These cells must be capable of sufficient self renewal in order to perpetuate the disease.
niche also plays important role in the pathogenesis of MDS. Interfering with this niche by targeting the molecular interactions between the stem cell and its microenvironment represents a novel therapeutic strategy.
driven. MDS is characterized by a pathological immune response triggered by abnormal haemopoietic stem cells that results in the autoimmune destruction of normal stem cells and/or their niche.
these patients, which also suggest role of immune system in the pathogenesis. T - cell - mediated inhibition of haemopoieis appears to be an important aspect of this mechanism, with oligoclonal CD8 + cytotoxic T cells being found in many patients. However, the antigens produced by the MDS cells that lead to these T - cell responses are largely unknown.
Apoptosis in MDS:
In cases of MDS that lack an excess of blasts, the
appears to be a necessary requirement for progression to leukaemia. This progression is accompanied by a change in favour of pro apoptotic proteins such as c - Myc in CD34 positive precursors at diagnosis to anti - apoptotic proteins such as Bcl - 2 in leukaemic blasts at time of transformation. Patients with higher rates of apoptosis have a considerably better overall survival than patients with lower rates of apoptosis.
TNF - , Fas - ligand, and TNF related apoptosis inducing ligand (TRAIL) These cytokines are typically upregulated in the marrow. Apoptosis can also be triggered by cytotoxic T cells and by signals from marrow stromal cells, probably via activation of similar pathways. This balance of pro - apoptotic to anti - apoptotic signals swings in favour of the latter as the MDS evolves towards AML.
Cytogenetic abnormalities:
Clonal abnormalities are observed in approximately
50% of all primary MDS cases and 90% of cases of secondary therapy - related MDS.
include: loss of Y, 5q or monosomy 5, 7q or monosomy 7, trisomy 8, 20q , abnormalities of 11q23, deletions of 17p, 12p, 13q and 11q None of these is specific for MDS as they can also occur in AML and myeloproliferative states.
score according to established prognostic scoring systems. Good risk karyotypes: normal, Y, del(5q) del(20q) Poor - risk karyotypes: chromosome 7 anomalies, complex (more than three abnormalities) very complex (more than five abnormalities)
del(20q) del(17p)
del(13q) del(11q) del(12p)
5-10 <5
<5 <5 <5
have been identified in MDS. These include genes coding for: cell surface molecules, signal transduction proteins, transcriptional factors, epigenetic modifiers, protein degradation pathways many genes of unknown function
induced MDS. In contrast with the mutations of AML1 found in M0 AML that are often biallelic, those found in MDS are generally monoallelic and result in AML1 haploinsuffi ciency rather than a dominant negative protein. Mutations in MDS occur more frequently in the C terminus of the protein causing truncation and loss of its transactivating domain. Individuals who inherit one abnormal copy of the AML1 gene commonly exhibit congenital thrombocytopenia with a propensity to develop AML, suggesting the gene might be acting as a tumour suppressor gene.
Isolated del(20q):
lineages.
Carries favourable prognosis
CMML,
Often associated with AML1 point mutations
V617F mutation of the JAK2 gene: Demonstrated in up to 50% of patients with the
overlap condition of RARS with thrombocytosis (RARS - T) This mutation causes constitutive activation of the JAK2 protein and downstream signalling.
mutations of the MPL gene, which are described in
TET2 gene mutations: TET2 gene is located within a region of UPD at 4q24 . It is a candidate tumour suppressor gene mutated in
with other myeloid malignancies, ie CMML (22%) secondary AML (24%) myeloproliferative disorders (12%).
identifiable in haematopoietic stem cells that is generally acquired before other mutations, such as the JAK2 V617F mutation.
The CBL gene at 11q23.3 is another candidate tumour
Abnormal gene
KIT , FMS , PDGFRB , GCSFR , MPL , FLT3 NRAS , JAK2 A ML1 , G ATA - 1 , P U.1 , C EBPA , TP53 M LL , ATRX CBL TET2
Epigenetic abnormalities:
Two important epigenetic modifications relevant to
can occur wherever this is followed by a guanine within a CpG dinucleotide pair. In normal cells, these CpG islands are typically unmethylated, allowing genes to be expressed. However, if a CpG island is methylated, then transcriptional activity at the promoter is impeded and the gene becomes silenced. Aberrant promoter methylation leads to inactivation of the gene, thereby providing an alternative mechanism whereby tumour - suppressor genes can be functionally deleted. This is the rationale for using hypomethylating agents as a novel therapeutic strategy in MDS
Histone modification: Histones form the chromatin scaffold and closely regulate
whether the DNA exists locally in a repressed or permissive state. Biochemical alterations to the tails of the histone molecules influence the degree of compaction of the nucleosomes and hence the level of transcriptional activity of nearby genes. There is a close and cooperative interplay between these two epigenetic control mechanisms that together can render a gene permanently silenced. The significance of this is that combination epigenetic therapies that comprise a hypomethylating agent with a histone deacetylase inhibitor may be more effective than single agents in reawakening silenced tumour - suppressor genes.
Diagnosis:
Depends on:
Clinical features Blood count Peripheral blood morphology Bone marrow morphology Bone marrow histology
Clinical features:
App. 20% of cases of MDS are detected incidently -
unexpected cytopenia or dysplasia. Remainder 80% patients presents with symptoms and signs of bone marrow failure,ie anaemia (80%) infections or bleeding ( 20%) Features of lymphadenopathy, splenomegaly and hepatomegaly are rarely found.
Blood count:
Anaemia (most common presentation) pancytopenia ( 30 50% cases)
30%). Isolated neutropenia or thrombocytopenia ( 5-10% ) Occasionally blood count may be normal.
dimorphic. Microcytosis is rare. Ocassionally dysplastic or megaloblastic erythroblasts are seen in PF.
Circulating blasts:
May be found in all categories of MDS but if present
are seen.
Auer rods are sometimes present.
platelets:
Often reduced platelets may show dysplasia , ie
hypogranulated or agranular forms giant forms. MDS patients have high incidence of autoimmune thrombocytopenia.
of lineages.
Reticulin can be modestly increased.
DYSGRANULOPOIESIS: Small or usually large size Nuclear hypolobation ( pseudo pelger-huet ) Irregular hypersegmentation Decreased granules or agranularity Pseudo chediak-higashi granules Auer rods
DYSMEGAKARYOCYTOPOIESIS:
Micromegakaryocytes Nuclear hypolobation multinucleation
(ALIP),ie groups of granulocytic precursors in the central parts of intertrabecular spaces and erythroid precursors and megakaryocytes in the para-trabecular regions.
Cytochemistry:
Iron staining for iron stores, ring sideroblasts and
Auer rods.
Non - specific esterase stains - monoblasts and
promonocytes.
NSE and PAS stains abnormal megakaryocytes.
Immunophenotyping:
Reduced expression of normal myeloid markers, and
worse prognosis.
DIFFERETIAL DIAGNOSIS:
Exclude: Other causes of anaemia (haematinic deficiency,
aplastic anaemia).
neutrophilia (infection,CML).
Reactive causes of BM dysplasia: megaloblastic
IPSS WPSS
IPSS:
Score value Bone marrow blasts (%) 0 <5 0.5 5-10 1.0 1.5 11-20 2.0 21-30
Karyotype
Cytopenias
good
0/1
intermediat poor e
2/3 -
WPSS:
Score value WHO category 0 1 2 RAEB- 1 3 RAEB- 2 RA, RARS, 5q RCMD, RCMD- RS
Karotype
Transfusion requirement
good
no
Intermediate
Regular
poor
-
5-6
136
63
44
19
MANAGEMENT OF MDS:
SUPPORTIVE CARE:
Supportive care includes:
blood products with deferoxamine.
IMMUNOSUPPRESSION:
Include polyclonal immunoglobulin preparations, ie
rabbit antithymocyte globulin (ATG) horse antilymphocyte globulin (ALG) Patients with Low IPSS score and marrow
MDS, a trial of immunosuppression with ATG should be considered first - line treatment before proceeding to allogeneic transplantation
CHEMOTHERAPY:
Treatment of MDS patients with intensive
chemotherapy regimens generally yields: low remission rates and high relapse rates.
The karyotype appears to be the major determinant
sensitize the cells to these drugs has not been shown to confer any significant clinical benefit.
AUTOLOGOUS SCT:
Consolidation of remission by way of autologous SCT
is only applicable to a minority of patients due to the difficulty in harvesting CD34 - positive progenitors from patients with MDS. Despite achieving stable engraftment after myeloablative high - dose chemotherapy, the graft is likely to be contaminated with residual disease cells that inevitably compromise any clinical benefit.
ALLOGENEIC SCT:
The optimal timing of transplantation in MDS is
after two or three cycles of intensive chemotherapy, since progressive or relapsed disease at time of SCT has a major adverse influence on outcome.
without total body irradiation, were used at high dose to condition the patient by way of total myeloablation allowing disease - free allogeneic stem cells to reconstitute the bone marrow.
But as Allogeneic SCT is associated with extremely high
HYPOMETHYLATING DRUGS:
MOA: Hypomethylating agents are incorporated into
the DNA where they covalently bind to the methyltransferase molecule, thereby inhibiting its function and leading to loss of methylation as DNA is replicated during mitosis. Currently, there are two hypomethylating agents that are approved for use in the treatment of MDS:
IMMUNOMODULATORY DRUGS:
Lenalidomide.
It have broad activity on the bone marrow
microenvironment, including anti angiogenic activity and cytokine suppression. It also causes enhancement of erythropoietin receptor signalling. Most marked responses are observed in those patients with del(5q) compared with normal karyotype or other cytogenetic abnormalities (83% vs. 57% vs. 12%, respectively).
monocyte count.
5q syndrome: clinically distinct form of MDS in WHO classification.
features are also present in myeloid or megakaryocytic lineages (RCMD-RS in WHO classification; 56% OS at 3yrs) and very low risk of AML.
and increased pollution. Multiple chromosomal abnormalities in almost all patients. Poorer prognosis than de novo MDS. Hypoplastic MDS: <15% of cases of MDS have hypocellular BM on biopsy. Dysplastic megakaryocytes, myeloid cells or excess blasts should be present. Difficult to distinguish from aplastic anaemia. May respond to immunosuppressive therapy.
<15% have marked fibrosis. More common in secondary MDS. PB shows pancytopenia and dysplastic features and sometimes leucoerythroblastic picture. BM hypercellular with myelofibrosis. Rapid deterioration usual.